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he VESTASYNC I Trial
. Ribamar Costa JR, MD,* Alexandre Abizaid, MD, PHD,* Ricardo Costa, MD,*
austo Feres, MD, PHD,* Luiz Fernando Tanajura, MD, PHD,* Andréa Abizaid, MD, PHD,*
alo Maldonado, MD,* Rodolfo Staico, MD,* Dimytri Siqueira, MD,*
manda G. M. R. Sousa, MD, PHD,* Raoul Bonan, MD,† J. Eduardo Sousa, MD, PHD*
ão Paulo, Brazil; and Quebec, Canada
bjectives We sought to assess the safety and efﬁcacy of the novel VESTAsync-eluting stent (MIV
herapeutics, Atlanta, Georgia) combining a stainless steel platform with a nanothin-microporous
ydroxyapatite surface coating impregnated with a polymer-free low-dose of sirolimus (55 g).
ackground Durable polymers in ﬁrst-generation drug-eluting stents (DES) have been linked to lo-
al inﬂammatory reaction leading to a positive vessel remodeling, late incomplete stent apposition,
nd in some cases, stent thrombosis. The removal of the polymer from the DES system could in-
rease the safety proﬁle of this novel technology.
ethods A total of 15 patients with single de novo lesions in native coronary arteries with 3.0- to
.5-mm diameter and 14-mm length were enrolled in this ﬁrst-in-man study. Primary end point
as in-stent late lumen loss (LL) at 4 and 9 months.
esults Baseline characteristics included mean age of 63 years and 33% of diabetics. Reference ves-
el diameter and lesion length were 2.7  0.3 mm and 10  2.0 mm, respectively. Procedure suc-
ess was obtained in all cases. Lifelong aspirin and 5-month clopidogrel treatment were prescribed
o all patients. At 4 months, in-stent LL and percentage of neointimal hyperplasia were 0.3  0.25
m and 2.6  2.2%, respectively, with a nonsigniﬁcant increase at 9 months (0.36  0.23 mm and
.0  2.2%, respectively). Serial intravascular ultrasound did not show late incomplete stent apposi-
ion. There were no major adverse cardiac events within 1 year of follow-up.
onclusions The novel VESTAsync-eluting stent was effective in reducing LL and neointimal hyper-
lasia at 4 and 9 months, with no evidence of late catch-up by quantitative coronary angiography
r intravascular ultrasound. (J Am Coll Cardiol Intv 2009;2:422–7) © 2009 by the American College
f Cardiology Foundation
rom the *Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil; and the †Montreal Heart Institute, Quebec, Canada. Drs.
bizaid and Bonan serve as consultants for MIV Therapeutics. Patrick Serruys, MD, acted as Guest Editor for this paper.anuscript received November 10, 2008; revised manuscript received January 23, 2009, accepted February 11, 2009.
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423ue to its marked efficacy in reducing the need for repeat
esion revascularization, first-generation drug-eluting stents
DES) (Cypher, Cordis, Miami Lakes, Florida; and Taxus,
oston Scientific, Natick, Massachusetts) rapidly became
he first option for percutaneous coronary artery revascular-
zation (1–4) . However, mid- to long-term safety of these
ovel devices are still in question mostly because of the late
nd very late stent thrombosis, partially attributed to the
resence of a durable polymer (5–9).
Lower but still effective drug doses combined with
onpolymeric coatings may be beneficial in reducing these
dverse events. Recently developed, the VESTAsync-eluting
tent (MIV Therapeutics, Atlanta, Georgia) combines a
tainless steel platform with a nanothin-microporous hy-
roxyapatite surface coating impregnated with a polymer-
ree low-dose lipid-sirolimus mixture (55 g). In vitro
esting on crimped and expanded stents at 37°C in 7.4 pH
uffered saline demonstrates a drug release rate (in micro-
rams per time point, not percentage of loaded drug) that is
lmost the same as Cypher for the first hour. Thereafter the
elease rate slows down to less than half the rate of Cypher.
ne hundred percent of the sirolimus is expected to be
eleased within the first 3 months of the procedure and the
ydroxyapatite is stable over 4 months in an in vitro testing
nvironment. The in vivo lifetime of hydroxyapatite coating
anges from 9 to 12 months. After that period, it is expected
o completely dissolve (100% according to pre-clinical data).
The VESTASYNC I clinical trial represents the first
valuation of this third-generation DES for the treatment of
uman coronary lesions. Four-month angiographic and
ltrasonographic results as well as 6-month clinical out-
omes of this study have been previously reported (10). In
he present paper, we present the 9-month angiographic
nd intravascular assessment along with the 1-year clinical
esults of this novel nonpolymeric DES.
ethods
he VESTASYNC I trial was a prospective, nonrandom-
zed, single-center evaluation of the hydroxyapatite
olymer-free sirolimus-eluting stent in patients with de
ovo coronary lesions. Patient eligibility criteria, device
escription, and study procedure have been previously
etailed (10).
Briefly, the study population included consecutive patients
ith single, de novo coronary obstructions50% and100%
n arteries of 3.0 to 3.5 mm in diameter (visual assessment).
esions should not exceed 14 mm in length and had to be
re-dilated before the DES implantation. Patients treated
ithin 72 h of an acute myocardial infarction and/or requiring
ore than 1 stent to treat the target lesion were excluded from
his study. We also excluded patients with heavily calcified
esions, those with lesions at bifurcations or involving the
stium of the coronary vessel, patients with severe left ventric- slar dysfunction (left ventricular function 30%), those with
isible thrombus and also with contraindication to any of the
rotocol medications. Dual antiplatelet therapy (aspirin 
lopidogrel) was given for 5 months and then patients were
ept on aspirin only.
The protocol was approved by the local ethics committee
nd written informed consent was obtained from all patients
efore inclusion in the study.
ollow-up and study end points. After discharge, patients
ere clinically followed by medical appointment at 1, 3, 6,
, and 12 months. Up to 2-year clinical follow-up is
xpected by protocol.
Angiography and intravascular ultrasound (IVUS)
ollow-up were scheduled for 4 and 9 months after the
aseline procedure.
The primary end points of this analysis were in-stent
uminal late loss as measured by quantitative coronary
ngiography (QCA) and in-stent percentage volume ob-
truction by IVUS, measured at 4 months.
Secondary end points included acute success (angio-
raphic and procedure success),
umulative rate of major adverse
ardiac events (MACE) up to 2
ears, rates of target-lesion and
arget-vessel revascularization up
o 2 years, and in-stent luminal
ate loss and in-stent percentage
olume obstruction at 9 months.
ere we report the 9-month
n-stent luminal late loss and
n-stent percentage volume ob-
truction as well as 1-year cumu-
ative MACE and target lesion
evascularization rate.
Device success was defined by the presence of residual
tenosis 20% in the treated segment, in the presence of
IMI (Thrombolysis In Myocardial Infarction) flow grade
flow following implantation of the VESTAsync stent.
rocedure success was defined by device success associated
ith no in-hospital major adverse events. We defined
ACE as death, nonfatal myocardial infarction (Q- and
on–Q-wave), and need for repeat lesion revascularization
by new percutaneous intervention or coronary artery bypass
raft). All deaths were considered cardiac unless a clear
oncardiac reason was identified. Myocardial infarction was
efined by an increase in the creatine kinase-myocardial
and twice upper the normal limit with or without new Q
aves on the electrocardiogram.
CA analysis. Angiographic studies were performed at
aseline, post-procedurally, and at follow-up, in 2 orthog-
nal views, after the intracoronary administration of 100 to
00 g of nitroglycerin. The same angiographic angles
erformed at baseline were reproduced at the subsequent
Abbreviations
and Acronyms
DES  drug-eluting stent(s)
IVUS  intravascular
ultrasound
MACE  major adverse
cardiac events
MLD  minimum lumen
diameter
QCA  quantitative coronary
angiographytudies. Digital angiograms were analyzed offline with the use
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424f an automated edge-detection system (QCA-CMS, Medis
edical Imaging Systems, Nuenen, the Netherlands).
Lesion morphology was assessed by using standard crite-
ia, and lesion complexity defined according to the modified
merican College of Cardiology/American Heart Associa-
ion classification system. A contrast-filled catheter tip was
sed for calibration.
Quantitative angiographic parameters included: 1) refer-
nce vessel diameter; 2) minimum lumen diameter (MLD);
) lesion length; 4) percent diameter stenosis (difference
etween the reference diameter and MLD divided by the
eference diameter and multiplied by 100); and 5) late
uminal loss (difference between MLD at the end of the
rocedure and MLD at follow-up). Quantitative analysis
as performed in the “in-stent” area (inside the stented
egment) and in the “in-lesion” segment, including the
tented area as well as both 5 mm proximal and distal to the
tent. In-stent and -lesion restenosis were defined as 50%
iameter stenosis at follow-up located within the stent and
he target lesion, respectively.
VUS analysis. Intravascular ultrasound studies were per-
ormed immediately after the procedure and at follow-up,
fter an intracoronary administration of 100 to 200 g of
itroglycerin.
All IVUS studies were performed with a motorized
utomatic transducer pullback system (0.5 mm/s) and com-
ercially available scanners (i-Lab, Boston Scientific) con-
isting of a rotating 40-MHz transducer catheter (Atlantis
R Pro, Boston Scientific) with a 2.6-F imaging sheath.
he images were digitalized for offline quantitative analysis
ccording to the American College of Cardiology’s Clinical
xpert Consensus Document on IVUS. Quantitative IVUS
nalysis was made using a commercially available comput-
rized planimetry program (EchoPlaque, INDEC Systems,
ountain View, California).
Quantitative parameters of lumen, stent, and vessel (ex-
ernal elastic membrane) cross-sectional areas were deter-
ined. Neointimal area was calculated as the stent area
inus the lumen area at the follow-up. Late lumen area loss
as calculated as the minimum lumen area following initial
tent deployment minus the minimum lumen area within
he stented segment at follow-up. Lumen, stent, vessel and
eointimal volumes were calculated using the Simpson rule.
ercent of neointimal volume obstruction was determined
y the neointimal volume at follow-up divided by the
ollow-up stent volume and multiplied by 100.
Incomplete stent apposition was defined as1 stent strut
learly separated from the vessel wall with evidence of blood
peckles behind the struts and was classified as: 1) persistent
when present both in the post stent implantation and
ollow-up studies); 2) late-acquired (when not present after
tent implantation, but detectable at the follow-up study);
nd 3) resolved (when present after stent implantation, but
ot detectable at the follow-up study).The QCA and IVUS analyses were performed by inde-
endent core laboratories at Cardiovascular Research Cen-
er, São Paulo, Brazil.
tatistical analysis. Continuous variables are expressed as
ean  SD. Comparisons between post-intervention and
ollow-up measurements were performed with 1-way
epeated-measures analysis of variance and post-hoc tests as
ppropriate. A p value 0.05 was considered statistically
ignificant.
esults
uring May 2007, a total of 15 consecutive patients who
atched the inclusion/exclusion criteria were treated with
he VESTAsync-eluting stent and included in this analysis.
ost patients were male (60%) with low to moderate profile
f clinical and angiographic complexity (Table 1). Proce-
ural as well as in-hospital outcomes have been previously
resented (10).
Table 1. Baseline Patient, Lesion, and Procedure Characteristics
Characteristics Patients (n  15)
Mean age, yrs 63.8 11.4
Female 6 (40%)
Hypertension 9 (60%)
Dyslipidemia 7 (47%)
Diabetes 5 (33%)
Smoking 7 (47%)
Family history of CAD 6 (40%)
Previous MI 7 (47%)
Previous CABG 2 (13%)
Treated coronary artery
LAD 7 (47%)
LCX 4 (25%)
RCA 4 (25%)
Lesion complexity*
Type A 1 (7%)
Type B1 3 (20%)
Type B2 11 (73%)
Pre-dilation 15 (100%)
Post-dilation 7 (47%)
Number of stents per lesion 1.0
Mean ﬁnal deployment pressure, atm 12.4 2.1
Pre-procedure QCA
Mean reference vessel diameter, mm 2.67 0.32
Mean lesion length, mm 9.98 1.98
Minimum lumen diameter, mm 0.98 0.29
Diameter of stenosis, % 63.5 9.90
Angiographic success 15 (100%)
Procedure success 15 (100%)
Values are mean  SD or n (%). *According to American College of Cardiology/American Heart
Association classification.
CABG  coronary artery bypass graft; CAD  coronary artery disease; LAD  left anterior
descending artery; LCX  left circumflex coronary artery; MI  myocardial infarction; QCA quantitative coronary angiograph; RCA right coronary artery.
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425-month QCA analysis. All patients returned at 9 months for
n invasive evaluation (Table 2). Therefore, serial QCA
valuation (baseline, post-procedure, 4-, and 9-month) was
vailable to the entire cohort.
At 9 months, in-stent MLD, percentage of diameter
tenosis, and lumen loss were 2.28  0.38 mm, 15.9 
.20%, and 0.36  0.23 mm, respectively. As compared
ith the post-procedure and 4-month evaluations, the
esults were sustained (Fig. 1A).
Figure 2A shows the distribution of in-stent late loss
mong the 15 patients at 9 months. Of note, the vast
ajority of patients had a late loss0.5 mm. Only 2 outliers
ad a more pronounced, focal neointimal formation. None
f the patients presented binary restenosis.
-month IVUS analysis. Adequate IVUS images were ob-
ained in all patients at 9-month follow-up (Table 2).
ESTAsync eluting stent elicited minimum neointimal
roliferation as demonstrated by the very low in-stent
eointimal volume and in-stent volume of obstruction (6.1
4.2 mm3 and 4.0  2.2%, respectively).
Serial IVUS examination (baseline, 4-, and 9-month) was
btained in 14 cases. In 1 case, IVUS image at 4-month
ollow-up was deemed inappropriate for analysis and, there-
ore, this patient was excluded from serial evaluation.
Figure 1. Quantitative Coronary Angiography and Intravascular Ultrasound
(A) In-lesion percentage of diameter of stenosis (DS) and minimum lumen diam
Table 2. 9-Month QCA and IVUS Results (n  15)
QCA
In-stent MLD, mm 2.28 0.38
In-stent DS, % 15.9 8.20
In-stent late lumen loss, mm 0.36 0.23
Binary restenosis, % 0
IVUS
In-stent neointimal volume, mm3 6.1 4.2
In-stent volume of obstruction, % 4.0 2.2
DS  diameter stenosis; IVUS  intravascular ultrasound; MLD  minimum lumen diameter;
other abbreviations as in Table 1.tion among post-procedure, 4-, and 9-month follow-ups.ompared with 4-month results, there was a slight, non-
ignificant increase in the amount of in-stent neointima
yperplasia (2.8  2.2 mm3 vs. 4.0  2.2 mm3, p  0.4).
mportantly, vessel, stent, and lumen volumes did not
ignificant vary from post-procedure to 4- and 9-month
valuations (Fig. 1B). Notably, in all patients, the percent-
ge of stent obstruction was 10% at 9 months (Fig. 2B).
The 2 cases of acute incomplete stent apposition observed
n the baseline IVUS analysis persisted at 9 months, with a
onsignificant decrease in the volume of malapposition
0.25  0.75 mm3 at baseline vs. 0.11  0.13 mm3 at 4
onths and 0.09 0.3 mm3 at 9 months, p 0.3). No case
f late acquired incomplete stent apposition was observed in
his series.
-year major adverse events and clinical outcomes. At the
2-month clinical follow-up, all patients were asymptomatic
ith negative noninvasive ischemia test. There were no
ajor adverse clinical events, including cardiac/noncardiac
eath, cerebrovascular accident, nonfatal myocardial infarc-
ion, and stent thrombosis.
iscussion
he 1-year results of the VESTASYNC I trial confirm the
ustained efficacy of this nonpolymeric elution of low-dose
irolimus for the treatment of noncomplex de novo coronary
esions, with no late adverse events.
Sirolimus potent antiproliferative properties have been
xtensively demonstrated following its local coronary deliv-
ry using a durable polymer (Cypher) (3,4). However,
ehilli et al. (11) in a recent comparison among 3
irolimus-eluting stents with different coating strategies
durable and biodegradable polymers vs. polymer-free for-
ulation) showed the inferiority of the nonpolymeric DES
n suppressing the neointimal tissue proliferation when
ompared with the 2 other formulations (11). At invasive
Parameters
(MLD) over a period of 9 months. (B) Vessel, lumen, and stent volume varia-Main
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426ollow-up (6 to 8 months), late lumen loss following the use
f the polymer-free sirolimus formulation was 0.47  0.56
m vs. 0.17  0.45 mm and 0.23  0.46 mm with the
urable polymer and biodegradable polymers, respectively
p  0.001). As a result, patients treated with the polymer-
ree DES had significantly higher angiographic and clinical
estenoses. Despite the differences in the populations of the
studies, in the present analysis, the hydroxyapatite non-
olymeric sirolimus-eluting stent was shown to elicit, at a
imilar time point assessment, less neointimal tissue forma-
ion than the polymer-free system used in the ISAR-
EST-3 (Intracoronary Stenting and Angiographic Reste-
osis Investigators–Test Efficacy of Rapamycin-Eluting
tents with Different Polymer Coating Strategies) trial.
Of note, the efficacy of the VESTAsync DES was achieved
ith a very low dose of sirolimus (2.9 g/mm vs. 7.8 g/mm
n Cypher). Pre-clinical analysis and studies with ex vivo
uman models have pointed to more inflammatory reaction
nd delayed local healing following higher doses of antiprolif-
rative agents (e.g., in DES overlapping segments) (12,13).
Finally, recent serial invasive studies with second-generation
ES (Endeavor, Medtronic, Minneapolis, Minnesota)
howed a marked increase in late loss and percentage of
tent neointimal obstruction following the implant of those
evices (14). Although the increase did not translate to
igher rates of ischemia-driven restenosis in those trials, the
esults raised concern about long-term maintenance of the
ood initial results obtained with the second-generation
ES. It is important to stress the lack of late catch-up
esponse following the use of the VESTAsync stent in this
nalysis. Although the sample size might be underpowered
o assess its impact on clinical restenosis, the sustained
uppression of late loss (QCA) and percentage of stent
bstruction (IVUS) observed between the 4- and 9-month
Figure 2. In-Stent Late Luminal Loss and Percentage of Stent Obstruction
Cumulative distribution curves of in-stent late lumen loss (A) and percentageollow-ups may indirectly support this premise.tudy limitations. The small sample size included in this
tudy precludes definite conclusions about the safety of this
ovel DES. Additionally, long-term follow-up (24
onths) in more complex scenarios is necessary to confirm
hese enthusiastic preliminary results.
onclusions
he novel VESTAsync sirolimus-eluting stent was effective
n reducing lumen loss (0.30 mm) and neointimal hyper-
lasia formation (2.8%) at 4-month angiographic follow-up.
hese initial results were sustained at 9-month follow-up
0.36 mm and 4.0%, respectively), with no evidence of late
atch-up by QCA and IVUS evaluation (p  NS). In
onfirming the present findings by large, randomized trials,
his novel technology is likely to represent a major advance
n the percutaneous treatment of coronary artery disease.
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